→· 1 event in window
Loading interest
Novo Nordisk suffered a major setback in early August as its heart drug ziltivekimab failed to meet the primary endpoint in a Phase 3 trial. The company's shares plunged on the news, wiping out over $30 billion in market value. The failure eliminates a key non-obesity growth opportunity, intensifying pressure amid competition from rivals like Eli Lilly.
On July 31, 2026, Novo Nordisk announced its experimental heart drug ziltivekimab failed to reduce major adverse cardiovascular events in a Phase 3 trial involving over 6,300 high-risk patients. The stock fell up to 10%, wiping out over $30 billion in market value. The failure removes a key non-obesity growth opportunity, as the company faces intense competition from Eli Lilly and a 70% share decline from its mid-2024 peak.
On July 21, 2026, Novo Nordisk filed a federal lawsuit in the U.S. District Court for the District of New Jersey against Eli Lilly, alleging false advertising for its obesity drug Zepbound and diabetes drug Mounjaro. Novo claims Lilly’s ads use outdated clinical data, comparing higher doses of Lilly’s drugs to lower doses of Novo’s Wegovy and Ozempic, while omitting newer data on Novo’s higher-dose Wegovy (7.2 mg) showing comparable weight loss. Novo seeks a permanent injunction, corrective advertising, and financial damages. Lilly defends its ads as based on head-to-head trial evidence. The case underscores fierce competition in the $120 billion global obesity drug market.
On July 31, 2026, Novo Nordisk announced its experimental heart drug ziltivekimab failed to reduce major adverse cardiovascular events in a Phase 3 trial involving over 6,300 high-risk patients. The stock fell up to 10%, wiping out over $30 billion in market value. The failure removes a key non-obesity growth opportunity, as the company faces intense competition from Eli Lilly and a 70% share decline from its mid-2024 peak.
A US federal judge allowed parts of a shareholder lawsuit against Novo Nordisk to proceed, alleging the company misled investors about the tolerability and trial design of its next-generation weight-loss drug CagriSema. The lawsuit centers on December 2024 clinical trial results showing average weight loss of 20.4%, below market expectations of 25%, which wiped billions off Novo's market cap. Investors claim Novo failed to disclose that only 57% of participants reached the highest dose due to a flexible dosing protocol, misleading statements about fixed-dose design and tolerability. The judge rejected most claims but allowed those related to tolerability and trial protocols to advance. Novo denies wrongdoing and plans to vigorously defend itself. The case highlights intense competition in the GLP-1 drug market, particularly with Eli Lilly.
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging that Lilly's television ads for its weight-loss drug Zepbound are deceptive. The ads claim Zepbound leads to greater weight loss than Novo's Wegovy, citing a study showing 50 pounds lost versus 33 pounds. Novo argues the study is outdated, as a higher dose of Wegovy approved in March 2026 now yields an average loss of 47 pounds. Novo also claims misleading comparisons in ads for diabetes drugs Mounjaro and Ozempic. The lawsuit seeks a permanent injunction to halt the ads and a corrective campaign, plus unspecified lost profits. Analysts suggest damages may be immaterial, but halting the ads could benefit Novo. Eli Lilly's stock has risen 50% over the past year, while Novo's has fallen 27%. The global obesity drug market reached $66 billion in 2025 and is projected to hit $120 billion by 2030, with Lilly holding about 60% of the U.S. market.
On July 21, 2026, Novo Nordisk filed a federal lawsuit in the U.S. District Court for the District of New Jersey against Eli Lilly, alleging false advertising for its obesity drug Zepbound and diabetes drug Mounjaro. Novo claims Lilly’s ads use outdated clinical data, comparing higher doses of Lilly’s drugs to lower doses of Novo’s Wegovy and Ozempic, while omitting newer data on Novo’s higher-dose Wegovy (7.2 mg) showing comparable weight loss. Novo seeks a permanent injunction, corrective advertising, and financial damages. Lilly defends its ads as based on head-to-head trial evidence. The case underscores fierce competition in the $120 billion global obesity drug market.
Eli Lilly announced it will file for regulatory approval of its next-generation obesity drug retatrutide in the first quarter of 2027, delaying earlier plans for a 2026 submission to gather additional manufacturing and quality-control data. The decision follows positive results from two new Phase 3 trials, bringing the total to five successful late-stage studies. In one trial, adults with obesity and Type 2 diabetes lost up to 20.8% of their weight (nearly 50 pounds) over 80 weeks. In another, patients with severe obesity and established cardiovascular disease lost up to 22.6% (55.8 pounds) and showed reduced cardiovascular risk factors. Retatrutide, a 'triple G' drug targeting GLP-1, GIP, and glucagon, is positioned as the next pillar of Lilly's obesity portfolio after Zepbound and the newly launched pill Foundayo. TD Cowen analysts estimate retatrutide could generate $3.8 billion in sales by 2030. Common side effects include diarrhea, nausea, and constipation.
This financial analysis article from The Motley Fool, published on Yahoo Finance on July 22, 2026, recommends three dividend stocks for long-term income investors seeking stocks to buy and hold forever. The article highlights Pfizer (PFE) for its 6.9% forward dividend yield and pipeline of new drugs including obesity treatment MET-097i, despite post-COVID struggles. It also discusses Coca-Cola (KO) for its 64-year streak of dividend increases and stable consumer staples demand. The article emphasizes the importance of companies with longevity to sustain and grow dividends over time, noting that finding such stocks is challenging but possible. The piece includes promotional content for a separate investment signal service.
This article compares two healthcare ETFs: the iShares Global Healthcare ETF (IXJ) and the Simplify Health Care ETF (PINK). IXJ is a low-cost, diversified index fund with 110 holdings, a 0.40% expense ratio, and a 1.47% dividend yield, making it suitable for income-focused investors seeking steady exposure to global healthcare giants like Eli Lilly and Johnson & Johnson. PINK is an actively managed, concentrated fund with 58 holdings, a 0.51% expense ratio, and a 0.64% dividend yield. It has a mission-driven mandate: all net profits are donated to breast cancer research via Susan G. Komen. PINK has outperformed recently with a 32% one-year return, driven by innovative biotech and medtech names, but carries higher single-stock and strategy risk. The article advises that IXJ is better for diversification and low costs, while PINK appeals to those comfortable with concentration risk and wanting social impact.
Super Micro Computer (SMCI) shares surged 16% premarket after raising its Q4 FY26 gross margin outlook to 15%-17%, well above prior guidance of 8.2%-8.4%, driven by favorable customer and product mix. Revenue is expected near the low end of $11B-$12.5B guidance, with consensus at $11.73B. Backlog hit record levels with over $60 billion in new orders. Separately, President Trump announced a phased tariff plan on generic drug imports: zero tariffs for two years starting August 1, then 100% in August 2028, rising to 200% a year later, aiming to push production onshore. Over a dozen major pharma firms including Eli Lilly, Pfizer, and Novo Nordisk have committed to price cuts. Nike announced it will cut ties with thousands of online distributors in China starting January, shifting focus to its own website, app, and major platforms like Tmall and JD.com.
Jim Cramer, host of Mad Money, warned investors on CNBC's 'Squawk on the Street' on July 21, 2026, that excessive tech exposure could lead to severe losses. He urged trimming positions in high-flying tech stocks like Micron Technology (MU), which has surged 758% in the past year, and rotating into undervalued sectors. Cramer highlighted financials such as JPMorgan Chase (JPM) at 15 times earnings, Bank of America (BAC) at 14 times, and Wells Fargo (WFC) at 12 times as attractive buys. In healthcare, he recommended Eli Lilly (LLY) over Novo Nordisk (NVO), citing Lilly's strong GLP-1 drug sales and raised guidance. The article also promotes a free list of top 10 AI stocks from an analyst who called NVIDIA in 2010.
President Donald Trump announced a phased tariff plan on imported generic drugs, starting with zero tariffs for two years from August 1, 2026, followed by a 100% levy in August 2028 and a 200% levy in August 2029. The escalation is intended to penalize generic drugmakers that do not move production to the U.S. within the grace period. Patented and branded drugs remain under existing 100% tariffs. Major drugmakers including Eli Lilly, Pfizer, and Novo Nordisk have struck deals with Trump under his 'most favored nation' policy, exempting them from tariffs for three years in exchange for lowering U.S. drug prices. The policy has significant implications for India, which supplies nearly half of U.S. generic medicines, and China, which dominates upstream active pharmaceutical ingredient supply.
Novo Nordisk filed a lawsuit against rival Eli Lilly on Tuesday in federal district court in New Jersey, accusing the company of false advertising regarding the performance of its weight loss drugs. The lawsuit alleges that Lilly intentionally selected outdated studies to claim that its drugs Mounjaro and Zepbound lead to significantly more weight loss than Novo Nordisk’s Ozempic and other treatments. This legal action highlights the intense competition in the rapidly growing weight loss drug market, where both companies are major players. The case centers on the accuracy of comparative advertising claims, with Novo Nordisk seeking to challenge what it views as misleading marketing tactics by Lilly.
CNBC's Jim Cramer reaffirmed support for Eli Lilly during the Investing Club's Morning Meeting on July 21, 2026, despite a lawsuit from rival Novo Nordisk. Novo alleged Lilly's GLP-1 drug ads mislead consumers about superior efficacy, citing outdated comparisons before a higher Wegovy dose was approved. Cramer and portfolio director Jeff Marks dismissed the lawsuit as a 'nothing burger,' focusing on Lilly's strong injectable business outside the U.S. and its oral obesity pill Foundayo. The broader market rose, led by chipmakers like Intel, which surged 7% after landing Fortinet as its first named customer for third-party manufacturing. Salesforce was downgraded by Morgan Stanley, while Microsoft retained a buy rating despite concerns over its OpenAI relationship and Xbox headwinds. Other stocks discussed included 3M, General Motors, Danaher, Halliburton, and D.R. Horton.
Novo Nordisk (NYSE: NVO) offers a high dividend yield of 3.5%, significantly above the S&P 500 average and pharmaceutical sector average. The company is navigating a transition year in 2026 due to US price reductions and generic competition in India, particularly for its GLP-1 weight-loss drug Wegovy. However, the article argues that the long-term outlook is positive because GLP-1 drugs, like insulin, create recurring revenue streams as patients require lifelong treatment. Novo Nordisk has largely resolved supply issues and its new GLP-1 pill appears more effective than competitor Eli Lilly's offering. The high yield is attributed to Wall Street skepticism, but the company is building an annuity-like income stream in the weight-loss drug market to complement its insulin business.
Novo Nordisk (NYSE: NVO) offers a high dividend yield of 3.5%, significantly above the S&P 500 average and the pharmaceutical sector average of 1.5%. The company's dividend payout ratio of roughly 40% is considered safe. Novo Nordisk, historically focused on diabetes and insulin, is transitioning in 2026 due to U.S. price cuts and generic competition in India. However, its GLP-1 weight-loss drugs, particularly a new pill form of Wegovy, are seeing strong demand and are more effective than Eli Lilly's Foundayo. The company has resolved supply issues. The article argues that the current high yield presents an opportunity for dividend investors, as GLP-1 drugs create a recurring, annuity-like income stream similar to insulin.
The article reports that Claude AI, an AI agent, sold its entire stake in Eli Lilly (LLY), disagreeing with President Trump's recent praise of the company. Claude AI cited a full valuation at 25 times earnings, the lowest expected return in its portfolio, and Eli Lilly's oral weight-loss pill losing market share to Novo Nordisk's Wegovy. The AI noted that Trump's comments about a $3.5 billion manufacturing plant in Pennsylvania change nothing, and a pending pharma tariff decision on July 31 remains an overhang. The article also discusses Eli Lilly's aggressive deal spree funded by GLP-1 cash flow, including acquisitions in psychedelics, CAR-T, and AI drug discovery, and contrasts the bearish AI stance with a bull case centered on AI-driven R&D productivity and manufacturing scale. Eli Lilly stock is up about 6% year-to-date.
This Seeking Alpha analysis by Yiannis, a chartered accountant and former Deloitte/KPMG consultant, argues that Novo Nordisk (NVO) stock, up 27% since his last coverage, has further upside driven by the growing commercial traction of oral Wegovy. The author employs an investment style focused on asymmetric opportunities with 3-5X upside potential and a 2-3 year horizon. He discloses no current position but may initiate a long position in NVO within 72 hours. The article is a bullish commentary on the pharmaceutical company's weight-loss drug pipeline, not a breaking news event.
Citi has raised its price target on Novo Nordisk (NYSE:NVO) to DKK330 from DKK300 ahead of the company's second-quarter results on August 5, citing the strength of the Wegovy oral pill launch. The broker increased its 2026 sales and operating income estimates by 4% to 5%, and its earnings per share forecasts for 2027 to 2030 by around 7%, driven by currency movements and stronger second-quarter Wegovy trends. For Q2, Citi forecasts adjusted operating income of DKK27.2 billion (down 9% at constant currencies) on sales of DKK72.7 billion (down 1%), both excluding US 340B rebate effects. The declines reflect continued price pressure across obesity and diabetes franchises, partially offset by the oral Wegovy launch, forecast to contribute DKK4 billion ($630 million). Citi kept its neutral rating, seeing a guidance upgrade as expected and already priced in.
The European Commission has approved Novo Nordisk's Wegovy pill, a once-daily oral semaglutide 25 mg treatment for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, to be used alongside diet and exercise. This marks the first oral GLP-1 receptor agonist approved for weight management across all EU member states. The decision follows a positive opinion from the EMA's CHMP in May 2026 and is supported by the OASIS 4 clinical trial, which showed approximately 17% weight loss in participants versus 3% for placebo. About one-third of treated patients achieved 20% or greater weight loss. The safety profile was consistent with the injectable version. This is the fifth regulatory approval for the Wegovy pill, following authorizations in the US, UK, UAE, and Bahrain. Novo Nordisk plans to introduce the treatment in additional countries during the second half of 2026.
The European Commission has approved Novo Nordisk's Wegovy pill, a once-daily oral semaglutide 25 mg treatment for adults with obesity or overweight with at least one weight-related comorbidity. This marks the first GLP-1 receptor agonist available in tablet form for weight management across all EU member states. The approval follows a positive opinion from the European Medicines Agency in May 2026 and is supported by the OASIS clinical trial program, which showed approximately 17% weight loss compared to 3% for placebo. This is the fifth regulatory approval for the Wegovy pill after the US, UK, UAE, and Bahrain. Novo Nordisk plans to introduce the treatment in additional countries during the second half of 2026. The European Commission also approved the Wegovy 7.2 mg injection in a single-dose pen for obesity.
Two U.S. biotech companies, Akston Biosciences and OKAVA Pharmaceuticals, are testing experimental GLP-1 weight-loss treatments for overweight cats, marking an early attempt to bring blockbuster human obesity drugs into veterinary medicine. Akston is sponsoring a Cornell University clinical trial of a once-weekly injection, while OKAVA is testing a long-acting implant in a study called 'MEOW-1.' The trials come as 61% of U.S. cats are classified as overweight or obese, according to the Association for Pet Obesity Prevention. Analysts say the move fits a broader shift from premium pet food to medicalization in the $200 billion U.S. pet economy, with pet-food giants also investing in longevity products. Neither product is approved yet, and top-line results are expected later this year.
Two U.S. biotech companies, Akston Biosciences and OKAVA Pharmaceuticals, are testing experimental GLP-1 weight-loss treatments for overweight cats, marking an early attempt to bring blockbuster human obesity drugs into veterinary medicine. Akston is sponsoring a Cornell University clinical study of a once-weekly GLP-1 therapy, while OKAVA is testing a long-acting implant delivering medication for up to six months in a trial called 'MEOW-1.' Neither product is approved yet. The effort comes as 61% of cats evaluated by U.S. vets in 2022 were overweight or obese. Industry analysts say this fits a broader transformation of the $200 billion U.S. pet economy from premiumization into medicalization, with pet-food giants also investing in longevity and therapeutic nutrition products. Top-line trial results are expected later in 2026.
This analysis argues that while Eli Lilly's GLP-1 weight-loss drugs (Mounjaro, Zepbound) drive the majority of its revenue and stock surge, investors overlook the company's strategic use of cash from these drugs to build a diversified pipeline. Eli Lilly is acquiring companies like AtaiBeckley (psychedelic drugs) and Ventyx Biosciences (immunology) to prepare for future patent expirations. The company is also investing in immunology (Ebglyss sales up 141% YoY), oncology, and neuroscience, with non-weight-loss drug revenue growing 160% in Q1 2026. The article positions Eli Lilly as prudently managing its GLP-1 windfall to sustain long-term growth beyond the weight-loss drug market.
India's Central Drugs Standard Control Organization (CDSCO) has approved Novo Nordisk's weight loss drug Wegovy (semaglutide injection 2.4 mg) for a new indication: noncirrhotic metabolic dysfunction associated steatohepatitis (MASH), a form of fatty liver disease. This marks the first global and Indian approval of a GLP-1 RA for MASH in adults with moderate to advanced liver fibrosis, to be used alongside a reduced calorie diet and increased physical activity. The approval is based on the phase 3 ESSENCE trial, which showed that Wegovy resolved steatohepatitis in 63% of patients and reduced liver fibrosis in 37% of patients. Novo Nordisk India's managing director Vikrant Shrotriya called the approval an important milestone for addressing MASH, obesity, and related metabolic diseases.
This Yahoo Finance analysis examines the high-risk, high-reward nature of investing in weight-loss drug developers. It highlights how clinical trial results can cause massive stock swings, using Viking Therapeutics (up 500% over five years) and Skye Bioscience (down 99%) as contrasting examples. The article explains the drug development pipeline, noting that only about 8 of 100 programs reach approval, with Phase 2 being the biggest hurdle. It also covers the funding clock risk for clinical-stage biotechs and presents five ETF options for diversified exposure, noting that dedicated weight-loss funds have underperformed due to their focus on large caps like Lilly and Novo Nordisk. The piece concludes by mentioning M&A as another potential payoff, citing Lilly's acquisition of psychedelic-drug developer AtaiBeckley.
Microsoft Corporation launched Microsoft Frontier Company on July 2, 2026, with $2.5 billion in funding to help large enterprise customers deploy AI systems using their own data and workflows. The unit will initially work with clients including Unilever and Novo Nordisk, assisting them in selecting and integrating AI models from Microsoft and outside providers. This initiative addresses the growing enterprise need for AI integration, governance, security, and measurable business outcomes rather than just access to a single model. Microsoft already provides operating-system, productivity, cloud, database, and identity layers for many large organizations. Frontier Company extends this position by embedding AI engineering services within customer operations. The strategy also responds to customer concerns about proprietary data and internal expertise being handed over to a single model provider, as customers will retain work results and can use multiple models, preserving trust while supporting Azure, Copilot, and broader commercial relationships.
Novo Nordisk has announced that its oral formulation of Wegovy (semaglutide) demonstrated superior performance compared to Eli Lilly’s competing drug, orforglipron, in key measures of efficacy and tolerability. The pharmaceutical giant released new analyses derived from the Orion indirect treatment comparison and the Optic patient preference studies. These studies specifically compared the effects of 25-milligram oral semaglutide against 36-milligram orforglipron. According to Novo Nordisk, the oral version of Wegovy resulted in greater average weight loss for patients and exhibited lower odds of adverse events, indicating better treatment tolerability. This development highlights the intensifying competition in the GLP-1 weight loss medication market, where both companies are vying for dominance with oral alternatives to their injectable treatments. The findings suggest a potential competitive advantage for Novo Nordisk in the emerging sector of oral obesity treatments, potentially influencing market share and patient preference in the future.
At the 33rd European Congress on Obesity in Istanbul, Novo Nordisk presented findings from a post-hoc indirect treatment comparison between two oral GLP-1 receptor agonists approved for weight management in the US: Wegovy (oral semaglutide) and Foundayo (orforglipron). Due to the absence of head-to-head trials, researchers used data from the Phase III OASIS-4 and ATTAIN-1 trials, employing simulated treatment comparison and matching-adjusted indirect comparison methods to align patient populations. The analysis revealed that oral semaglutide demonstrated superior efficacy, with mean weight reduction exceeding orforglipron by approximately 3.0 to 3.2 percentage points. Furthermore, tolerability outcomes significantly favored Wegovy, as orforglipron was associated with a markedly higher risk of discontinuation due to adverse events and gastrointestinal issues. While key opinion leaders noted Wegovy's administration requirements as a potential disadvantage compared to orforglipron, the study highlights Wegovy's advantages in both efficacy and safety profile. These results are expected to influence clinical positioning and health technology assessments as competition in the oral obesity treatment market intensifies, with numerous candidates currently in development globally.
The American Society of Gene & Cell Therapy (ASCGT) and Orphan Therapeutics Accelerator (OTXL) have jointly launched CGTxchange, an artificial intelligence-enabled marketplace designed to revive shelved cell and gene therapy (CGT) assets. The platform aims to connect academics, investors, biotechs, and non-profit developers to reinvigorate development programs for assets previously discarded due to funding constraints rather than safety or efficacy issues. OTXL COO Beth White describes the platform as a two-sided marketplace similar to Zillow, offering a simplified scoring system for preclinical data, clinical efficacy, safety, and regulatory paths to help potential partners evaluate opportunities. The initiative addresses a growing trend where economic factors have forced major pharmaceutical companies, such as Novo Nordisk and Takeda, to pause or abandon CGT programs. By facilitating licensing and alternative financing models, including non-profit approaches, CGTxchange seeks to provide a new lease on life for promising but stalled therapies, particularly those targeting rare diseases, thereby improving accessibility and commercial viability in the sector.
This financial analysis evaluates whether investors should buy, sell, or hold Novo Nordisk stock at its current price of approximately $46. The article highlights that Novo Nordisk has underperformed the S&P 500 index in 2026, losing 7.5% while the broader market gained 8%. Although weight loss and diabetes treatments like Wegovy and Ozempic constitute over three-quarters of the company's sales, signs of market saturation and competition are emerging. Specifically, Ozempic sales declined by 8% year-over-year in the first quarter. The analyst points to intensifying competition from rivals such as Eli Lilly, which received FDA approval for its oral treatment Foundayo, and Pfizer, which expanded its pipeline by acquiring Metsera. Due to the company's heavy reliance on these specific drug treatments and the increasing competitive pressure eroding its market share, the author concludes that investors should sell their Novo Nordisk shares. The piece also notes that Novo Nordisk was excluded from the Motley Fool Stock Advisor's list of top ten stocks to buy, suggesting better opportunities exist elsewhere in the market.
This financial analysis argues that Hims & Hers Health (HIMS) stock is significantly undervalued following its first-quarter 2026 earnings report. Although the company faced negative market sentiment due to margin pressures caused by transitioning from compounded to branded GLP-1 medications, it successfully raised its full-year 2026 guidance and reaffirmed its long-term 2030 revenue and EBITDA targets. The author highlights that normalized gross margins remain robust and that marketing spend can be adjusted to improve profitability. A key growth driver identified is the partnership with Novo Nordisk, which is expected to bring in 100,000 new weight-loss subscribers monthly, potentially driving a 30–35% year-over-year increase in subscriber growth. Based on discounted cash flow (DCF) models, the analyst estimates the intrinsic value of the stock to be over $100 per share, suggesting substantial long-term growth opportunities through platform expansion. The article concludes with a strong buy recommendation, asserting that the current market price does not reflect the company's fundamental strength and future potential.